Early weakness (shares have since recovered) in Sarepta Therapeutics (SRPT +1.4%) is being...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Early weakness (shares have since recovered) in Sarepta Therapeutics (SRPT +1.4%) is being attributed at least in part to Deutsche's Robyn Karnauskas, who has some questions about Eteplirsen. Specifically, the analyst says FDA draft guidelines suggest a Breakthrough designation for the DMD treatment could be withdrawn if "another drug in same indication gains approval." The worry is that Prosensa's Drisapersen gets to market first. However, Karnauskas does think Eteplirsen has a "substantial safety advantage." (Also: Piper likes SRPT's DMD chances)